Arsanilic acid

Identification

Generic Name
Arsanilic acid
DrugBank Accession Number
DB03006
Background

An arsenical which has been used as a feed additive for enteric conditions in pigs and poultry. It causes blindness and is ototoxic and nephrotoxic in animals. [PubChem]

Type
Small Molecule
Groups
Experimental, Vet approved
Structure
Thumb
Weight
Average: 217.0542
Monoisotopic: 216.972014544
Chemical Formula
C6H8AsNO3
Synonyms
  • (p-aminophenyl)arsonic acid
  • 4-aminobenzenearsonic acid
  • 4-Aminophenylarsonic acid
  • 4-Aminophenylarsonsäure
  • 4-arsanilic acid
  • Arsanilic acid
  • Arsanilsäure
  • atoxylic acid
  • p-arsanilic acid
External IDs
  • AS 101

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
ULysozyme CNot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aniline and substituted anilines. These are organic compounds containing an aminobenzene moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Aniline and substituted anilines
Direct Parent
Aniline and substituted anilines
Alternative Parents
Pentaorganoarsanes / Oxygen-containing organoarsenic compounds / Organic metalloid salts / Primary amines / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Amine / Aniline or substituted anilines / Aromatic homomonocyclic compound / Hydrocarbon derivative / Organic metalloid salt / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organic salt / Organoarsenic compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
organoarsonic acid (CHEBI:49477)
Affected organisms
Not Available

Chemical Identifiers

UNII
UDX9AKS7GM
CAS number
98-50-0
InChI Key
XKNKHVGWJDPIRJ-UHFFFAOYSA-N
InChI
InChI=1S/C6H8AsNO3/c8-6-3-1-5(2-4-6)7(9,10)11/h1-4H,8H2,(H2,9,10,11)
IUPAC Name
(4-aminophenyl)arsonic acid
SMILES
NC1=CC=C(C=C1)[As](O)(O)=O

References

General References
Not Available
PubChem Compound
7389
PubChem Substance
46508500
ChemSpider
7111
ChEBI
49477
ChEMBL
CHEMBL351769
PDBe Ligand
ASR
Wikipedia
Arsanilic_acid
PDB Entries
1n4f

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2SuspendedTreatmentAcute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS)1
2TerminatedTreatmentAllergic Contact Dermatitis1
2TerminatedTreatmentThrombocytopenia Chemotherapy Induced1
2Unknown StatusTreatmentAlopecia1
2Unknown StatusTreatmentExternal Genital Warts1
2WithdrawnTreatmentMild to Moderate Psoriasis1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1, 2CompletedTreatmentCondylomata Acuminata / Wart; External Genital Organs1
1, 2CompletedTreatmentNeovascular Age Related Macular Degeneration1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections3

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility11.0 mg/mLALOGPS
logP-0.42ALOGPS
logP-0.17ChemAxon
logS-1.3ALOGPS
pKa (Strongest Acidic)3.95ChemAxon
pKa (Strongest Basic)2.73ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area83.55 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity36.75 m3·mol-1ChemAxon
Polarizability16.29 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.6659
Blood Brain Barrier+0.8643
Caco-2 permeable-0.5292
P-glycoprotein substrateNon-substrate0.8603
P-glycoprotein inhibitor INon-inhibitor0.9804
P-glycoprotein inhibitor IINon-inhibitor0.9897
Renal organic cation transporterNon-inhibitor0.929
CYP450 2C9 substrateNon-substrate0.824
CYP450 2D6 substrateNon-substrate0.8209
CYP450 3A4 substrateNon-substrate0.7607
CYP450 1A2 substrateNon-inhibitor0.7044
CYP450 2C9 inhibitorNon-inhibitor0.946
CYP450 2D6 inhibitorNon-inhibitor0.9492
CYP450 2C19 inhibitorNon-inhibitor0.9278
CYP450 3A4 inhibitorNon-inhibitor0.9412
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9499
Ames testNon AMES toxic0.759
CarcinogenicityNon-carcinogens0.5105
BiodegradationNot ready biodegradable0.9666
Rat acute toxicity1.9021 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9293
hERG inhibition (predictor II)Non-inhibitor0.9399
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Drugtargets
Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Learn more
Accelerate your drug discovery research with our ADMET & drug target dataset
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Lysozyme activity
Specific Function
Lysozymes have primarily a bacteriolytic function; those in tissues and body fluids are associated with the monocyte-macrophage system and enhance the activity of immunoagents.
Gene Name
LYZ
Uniprot ID
P61626
Uniprot Name
Lysozyme C
Molecular Weight
16536.885 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]

Drug created on June 13, 2005 13:24 / Updated on February 21, 2021 18:51